IP Library Granted Patent US 12,162,926
Granted Patent B2
US 12,162,926 · App. 17/487,690 · Granted Dec 10, 2024

Multi-specific antibodies for cross-neutralization of multiple filovirus glycoproteins

Inventors: Jonathan R. Lai (Dobbs Ferry, NY); Julia Frei (Bronx, NY); Elisabeth Nyakatura (New York, NY)
Assignee: Albert Einstein College of Medicine
C07K16/10A61K39/42C07K2317/24C07K2317/31C07K2317/622C07K2317/64C07K2317/76
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,162,926
App. No.
17/487,690
Granted
Dec 10, 2024
Kind
B2
Abstract

Methods for treating and for preventing filovirus infections are disclosed, as well as compositions therefor.

Claims (22)

1. A recombinant dual-variable-domain antibody comprising:

(1) a heavy chain amino acid sequence comprising in N terminal to C terminal order (i) a first V H amino acid sequence comprising at least one CDR directed to a membrane glycoprotein pre-fusion core of a first species of filovirus, (ii) a 4, 5, 6, 7, or 8 amino acid first linker sequence, (iii) a second V H amino acid sequence comprising at least one CDR directed to a membrane glycoprotein pre-fusion core of a second species of filovirus, (iv) an immunoglobulin G C H 1 amino acid sequence, (v) an immunoglobulin G hinge amino acid sequence, (vi) an immunoglobulin G C H 2 amino acid sequence, (vii) an immunoglobulin G C H 3 amino acid sequence, which is bound via one or more inter-chain disulfide bond(s) to

(2) a light chain amino acid sequence comprising in N terminal to C terminal order (i) a first V L amino acid sequence comprising at least one CDR directed to a membrane glycoprotein pre-fusion core of a first species of filovirus, (ii) a 4, 5, 6, 7, or 8 amino acid second linker sequence, (iii) a second V L amino acid sequence comprising at least one CDR directed to a membrane glycoprotein pre-fusion core of a second species of filovirus, (iv) an immunoglobulin G C L amino acid sequence, wherein the first species of filovirus and second species of filovirus are different species,

wherein the heavy chain comprises an amino acid sequence selected from SEQ ID NO: 43, 47, 51, or 55; and the light chain comprises an amino acid sequence selected from SEQ ID NO: 45, 49, 53, or 57.

2. The recombinant dual-variable-domain antibody of claim 1 , wherein (1) and (2) are bound via an inter-chain disulfide bond between the C H 1 amino acid sequence and the CL amino acid sequence.

3. A construct comprising two of the recombinant dual-variable-domain antibody of claim 1 joined together by one or more disulfide bonds between the heavy chain amino acid sequence of each.

4. The construct of claim 3 , wherein the two recombinant dual-variable-domain antibodies are joined together by two disulfide bonds between the immunoglobulin G hinge amino acid sequences of each.

5. The recombinant dual-variable-domain antibody of claim 1 , wherein the 4, 5, 6, 7, or 8 amino acid first linker sequence is a 6 amino acid first linker sequence.

6. The recombinant dual-variable-domain antibody of claim 5 , wherein the 6 amino acid first linker sequence is ASTKGP (SEQ ID NO:41).

7. The recombinant dual-variable-domain antibody of claim 1 , wherein the 4, 5, 6, 7, or 8 amino acid second linker sequence is 5 amino acid second linker sequence.

8. The recombinant dual-variable-domain antibody of claim 1 , wherein the 5 amino acid second linker sequence is TVAAP (SEQ ID NO:42).

9. The recombinant dual-variable-domain antibody of claim 1 , wherein the first V H amino acid sequence comprises three different heavy chain CDRs each of the three CDRs directed to the membrane glycoprotein pre-fusion core of the first species of filovirus.

10. The recombinant dual-variable-domain antibody of claim 1 , wherein the first V L amino acid sequence comprises three different light chain CDRs each of the three CDRs directed to the membrane glycoprotein pre-fusion core of the first species of filovirus.

11. The recombinant dual-variable-domain antibody of claim 1 , wherein the second V H amino acid sequence comprises three different heavy chain CDRs each of the three CDRs directed to the membrane glycoprotein pre-fusion core of the second species of filovirus.

12. The recombinant dual-variable-domain antibody of claim 1 , wherein the second V L amino acid sequence comprises three different light chain CDRs each of the three CDRs directed to the membrane glycoprotein pre-fusion core of the second species of filovirus.

13. The recombinant dual-variable-domain antibody of claim 1 , where in the first species of filovirus and the second species of filovirus are both Ebolavirus species.

14. The recombinant dual-variable-domain antibody of claim 13 , wherein the Ebola virus species are Zaire ebolavirus and Sudan ebolavirus.

15. An isolated nucleic acid encoding the recombinant dual-variable-domain antibody of claim 1 .

16. The recombinant dual-variable-domain antibody of claim 1 , wherein the recombinant dual-variable-domain antibody comprises SEQ ID NO: 43 and SEQ ID NO: 45.

17. The recombinant dual-variable-domain antibody of claim 1 , wherein the recombinant dual-variable-domain antibody comprises SEQ ID NO: 47 and SEQ ID NO: 49.

18. The recombinant dual-variable-domain antibody of claim 1 , wherein the recombinant dual-variable-domain antibody comprises SEQ ID NO: 51 and SEQ ID NO: 53.

19. The recombinant dual-variable-domain antibody of claim 1 , wherein the recombinant dual-variable-domain antibody comprises SEQ ID NO: 55 and SEQ ID NO: 57.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 4, 2024
From: LAI, JONATHAN R.; FREI, JULIA; NYAKATURA, ELISABETH
To: ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
Reel/Frame 066016/0364 →
MERGER AND CHANGE OF NAME Recorded Jan 4, 2024
From: ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.; ALBERT EINSTEIN COLLEGE OF MEDICINE
To: ALBERT EINSTEIN COLLEGE OF MEDICINE
Reel/Frame 066191/0005 →